A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10815-10823

  Liu, Fenghua ^a   Park, Peter J ^b,e   Lai, Weil ^b   Maher, Elizabeth ^a,c,d   Chakravarti, Arnab ^a   Durso, Laura ^c,d   Jiang, Xiuli ^a   Yu, Yi ^a   Brosius, Amanda ^a   Thomas, Meredith ^a   Chin, Lynda ^c,d   Brennan, Cameron ^c,d   DePinho, Ronald A ^c,d   Kohane, Isaac ^b,e   Carroll, Rona S ^a   Black, Peter M ^a   Johnson, Mark D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE NUMBER; GENE TARGETING; GENETIC SCREENING; GENOME; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

BRAIN NEOPLASMS; CELL GROWTH PROCESSES; GENOME, HUMAN; GLIOBLASTOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIGENE FAMILY; NUCLEIC ACID HYBRIDIZATION; RECEPTOR, EPHA2; RNA, MESSENGER;

EID: 33845332412     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1408     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
3. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25.
4. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65:1678-86.
5. Nakahara Y, Shiraishi T, Ojamoto H, et al. Detrended fluctuation analysis of genome-wide copy number proflies of glioblastomas using array-based comparative genomic hybridization. Neuro-oncol 2004;6:281-9.
6. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
7. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 2004;6:432-9.
8. Wolf M, Mousses S, Hautaniemi S, et al. A High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 2004;6:240-7.
9. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 2004;101:9067-72.
10. Tay ST, Leong SH, Yu K, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003;63:3309-16.
11. Wrobel G, Roerig P, Kokocinski F, Neben K, Reifenberger G, Lichter P. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005;114:249-56.
12. Wang P, Kim Y, Pollack J, Narasimhan B, Tibshirani R. A method for calling gains and losses in array CGH data. Biostatistics 2005;6:45-58.
13. Olshen A, Venkatraman E, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
14. Fridlyand J, Snijders A, Pinkel D, Albertson D, Jain A. Hidden Markov models approach to the analysis of array CGH data. J Multivariate Analysis 2004;90:132-53.
15. Lai WR, Johnson MD, Kucherlapati R, Park PJ. Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data. Bioinformatics 2005;21:3763-70.
16. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004;101:6062-7.
17. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
18. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
19. Fukuoka Y, Inaoka H, Kohane IS. Inter-species differences of co-expression of neighboring genes in eukaryotic genomes. BMC Genomics 2004;5:4.
20. Reyal F, Stransky N, Bernard-Pierrot I, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes-a study of 130 invasive ductal breast carcinomas. Cancer Res 2005;65:1376-83.
21. Bredel M, Bredel C, Juric D, et al. High resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 2005;65:4088-96.
22. Koschny R, Koschny T, Froster UG, Krupp W, Zuber MA. Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet 2002;135:147-59.
23. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81:717-23.
24. Mao X, Hamoudi RA. Molecular and cytogenetic analysis of glioblastoma multiforme. Cancer Genet Cytogenet 2000;122:87-92.
25. Brat DJ, Seiferheld WF, Perry A, et al. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group Trials. Neuro-oncol 2004;6:96-103.
26. Suzuki T, Maruno M, Wada K, et al. Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 2004;21:27-34.
27. Misra A, Pellarin M, Nigro J, et al. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 2005;11:2907-18.
28. Holder N, Klein R. Eph receptors and ephrins: effectors of morphogenesis. Development 1999;126:2033-44.
29. Phillips H, Kharbanda S, Ruihan C, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
30. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAPK/ERK kinase signaling cascade. Oncogene 2002;21:7690-9.
31. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7.
32. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004;320:1096-102.
33. Noblitt LW, Bangari DS, Shukla S, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004;11:757-66.
34. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004;23:1448-56.
35. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004;318:882-92.
36. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005;11:226-31.
37. Nakamura R, Kataoka H, Sato N, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 2005;96:42-7.
38. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145-50.
39. Wu D, Suo Z, Kristensen GB, et al. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol 2004;94:312-9.
40. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-6.
41. Brantley DM, Cheng N, Thompson EJ, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21:7011-26.
42. Coffman KT, Hu M, Carles-Kinch K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 2003;63:7907-12.
43. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.
44. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005;3:541-51.
45. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005;7:717-22.